Yuichi Yamamoto

发表

Association between Subclinical Atherosclerosis Markers and the Level of Accumulated Advanced Glycation End-Products in the Skin of Patients with Diabetes

I. Shimomura, T. Matsuoka, D. Kawamori, 2018, Journal of atherosclerosis and thrombosis.

Skin autofluorescence is associated with vascular complications in patients with type 2 diabetes.

I. Shimomura, T. Matsuoka, D. Kawamori, 2018, Journal of diabetes and its complications.

Identification of Plasma Inositol and Indoxyl Sulfate as Novel Biomarker Candidates for Atherosclerosis in Patients with Type 2 Diabetes. -Findings from Metabolome Analysis Using GC/MS-

E. Fukusaki, T. Bamba, I. Shimomura, 2020, Journal of atherosclerosis and thrombosis.

Preserving expression of Pdx1 improves β-cell failure in diabetic mice.

I. Shimomura, H. Kaneto, T. Matsuoka, 2017, Biochemical and biophysical research communications.

Sustained expression of GLP-1 receptor differentially modulates β-cell functions in diabetic and nondiabetic mice.

I. Shimomura, H. Kaneto, T. Matsuoka, 2016, Biochemical and biophysical research communications.

Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects

G. Nucci, V. Sahasrabudhe, D. J. Fediuk, 2021, Clinical pharmacology in drug development.

Aniridia with a heterozygous PAX6 mutation in which the pituitary function was partially impaired.

T. Funahashi, I. Shimomura, H. Kaneto, 2014, Internal medicine.

Clinical impact of genetic variants of drug transporters in different ethnic groups within and across regions.

Misaki Suzuki, Ichiro Ieiri, Katsuomi Ichikawa, 2013, Pharmacogenomics.

Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability – considerations for drug development

L. Tremaine, B. Feng, Y. Lai, 2012, Expert opinion on drug metabolism & toxicology.

Hyperthyroidism due to thyroid-stimulating hormone secretion after surgery for Cushing's syndrome: a novel cause of the syndrome of inappropriate secretion of thyroid-stimulating hormone.

I. Shimomura, Y. Hayashi, Toshiharu Onodera, 2013, The Journal of clinical endocrinology and metabolism.

Identification of Metabolites Associated with Onset of CAD in Diabetic Patients Using CE-MS Analysis: A Pilot Study

E. Fukusaki, T. Bamba, I. Shimomura, 2019, Journal of atherosclerosis and thrombosis.

Predictive factors for the efficacy of switch to oral hypoglycemic agents in Japanese type 2 diabetic patients with intensive insulin therapy temporarily introduced.

I. Shimomura, H. Kaneto, T. Matsuoka, 2014, Endocrine journal.

Association of coronary artery stenosis with carotid atherosclerosis in asymptomatic type 2 diabetic patients.

H. Kaneto, Y. Irie, Y. Umayahara, 2011, Journal of atherosclerosis and thrombosis.

Current Status, Issues and Future Prospects of Personalized Medicine for Each Disease

Yusuke Nakayama, Yuichi Yamamoto, N. Matsushima, 2022, Journal of personalized medicine.

Association between new onset diabetic retinopathy and monocyte chemoattractant protein-1 (MCP-1) polymorphism in Japanese type 2 diabetes.

I. Shimomura, T. Matsuoka, Y. Yamasaki, 2015, Diabetes research and clinical practice.

Case of aniridia with a heterozygous PAX6 mutation in which the glucagon response to arginine was evaluated

I. Shimomura, H. Kaneto, T. Matsuoka, 2015, Journal of Diabetes Investigation.

Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability – considerations for drug development

L. Tremaine, B. Feng, M. Varma, 2012, Expert opinion on drug metabolism & toxicology.